Design and evaluation of controlled release of piroxicam from the pellets of microcrystalline cellulose and hydroxypropylmethyl cellulose blends

International Journal of PharmTech Research

Volumn 2, Issue 2, 2010, Pages 1465-1473

  Rajesh, N ^a   Siddaramaiah, ^a  

^a SRI JAYACHAMARAJENDRA COLLEGE OF ENGINEERING   (India)

Author keywords

Binder; Eudragit; Pelletization; Piroxicam; Release kinetics

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; PIROXICAM;

ARTICLE; CLINICAL EVALUATION; CONTROLLED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PELLET; DRUG STABILITY; GASTROINTESTINAL IRRITATION; INFRARED SPECTROSCOPY; KINETICS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

EID: 77954697217     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vyas SP, Khar KK. Controlled drug delivery concepts and advances, CBS Pub; 2002, 1-12.
2. Ghebre-Sellassie I, Knoch A. Pelletization techniques Encyclopedia of Pharmaceutical Techno logy, Marcel Dekker Inc, New York:1995, 369-396.
3. Debunne A, Vervaet C, Mangelings D, Remon JP. Compaction of enteric-coated pellets: influence of formulation and process parameters on tablet properties and in vivo evaluation. Eur J. of Phar Sci, 2004, 22, 305-314.
4. Naikwade SR, Bajaj AN. Development and evaluation of once a day oral controlled multiparticulate drug delivery systems of cefixime trihydrate. Ind. J. Pharm Edu and Res, 2008, 42 (3), 283-294.
5. Elchidana PA, Deshpande SG. Microporous membrane drug delivery system for indomethacin J. Control. Rel, 1999, 59, 279-285.
6. Fekete R, Zelko R, Marton S, Racz I. Effect of the formulation parameters on the charactersitics of pellets. Drug Dev. Ind. Pharm, 1998, 24, 1073-1076.
7. Vervaet C, Baert L, Remon JP. Extrusion-spheronisation. A literature review, Int.J.Pharm, 1995, 116,131-146.
8. Keningley ST, Knight PC, Marson AD. An investigation into the effects of binder viscosity on agglomerate behaviour, Powder Technol, 1997, 91, 95-103.
9. Fekete R, Zelko R, Marton S, Racz I. Effect of the formulation parameters on the characteristics of pellets, Drug Dev.Ind.Pharm, 1998, 24(11), 1073-1076
10. Fielden K.E. Newton J.M. Rowe RC. Thermal studies on the interaction of water and microcrystalline cellulose. J.Pharm. Pharmacol, 1989, 41, 217-221.
11. Fekete R, Marton S, Farkas E, Racz I. Physical properties of pellets manufactured in the high shear mixer after optimizing the process parameters, Pharmazie, 1999, 54 (3), 200-202.
12. Sinha VR, Agrawal MK, Kumria R, Bhinge JR. Influence of operational variables on properties of piroxicam pellets prepared by extrusion-spheronization: A technical note. AAPS Pharm Sci and Tech, 2007, 8.
13. Huang AY, Berg JC. Gelation of liquid bridges in spherical agglomeration. Colloids and Surfaces, 2002, 1-12.
14. Willett CD, Adams MJ, Johnson SA, Seville JPK. Effects of wetting hysteresis on pendular liquid bridges between rigid spheres. Powder Technology, 2003, 130, 63-69.
15. Heng PWS, Staniforth JN. The effect of moisture on the cohesive properties of microcrystalline celluloses. J. Pharm. Pharmacol, 1998, 40, 360-362.
16. Rough SL, Bridgwater J, Wilson DI. Effects of liquid phase migration on extrusion of microcrystalline cellulose pastes. Int. J. of Pharm, 2000, 204(1-2), 117-126.
17. Alsop S, Matchett AJ, Coulthard JM, Peace J. Elastic and cohesive properties of wet particulate materials. Powder Technology, 1997, 91, 157-164.
18. Kanaze FI, Kokkalou E, Niopas I, Georgarakis M, Stergiou A, Bikiaris D. Dissolution enhancement of flavonoids by solid dispersion in PVP and PEG matrixes: A comparative study. J Appl Polym Sci, 2006, 102, 460-471.
19. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions inhydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm, 2007,66,334-347.
20. Kumar SGV, Mishra DN. Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG 6000. J Pharm Soc Jpn, 2006, 126, 657-664.
21. Debunne A, Vervaet C, Remon JP. Development and in vitro evaluation of an enteric-coated multiparticulate drug delivery system for the administration of piroxicam to dogs. Eur J. of Pharm and Biopharm, 2002,54, 343-348.
22. Dahl SL, Ward JR. Pharmacology, clinical efficacy and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy, 1982, 2, 80-89.
23. Mckellar QA, May SA, Lees P. Pharmacology and therapeutics of non-steroidal anti-inflammatory drugs in the dog and cat: 2 individual agents. J. of Small Animal Practice, 1991, 32, 225-235.
24. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury.Ame J. of Medi, 1996,101, 25S-32S.
25. Rubin SI, Papich MG. Clinical uses of nonsteroidal anti-inflammatory drugs in companion animal practice. Part ii. Drugs, therapeutic uses and adverse effects. Canine Practice, 1990,15, 27-33.
26. Bjarnasson I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local Versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut, 1991, 32, 275-277.
27. Reuter B, Davies N, Wallace J. Nonsteroidal anti-inflammatory drug enterohepathy in rats: role of permeability, bacteria and enterohepatic circulation. Gastroenterology, 1997,112, 109-117.
28. Polli J, Bigora S, Piscitelli D, Straughn A, Young D. Pavlovian food effect on the enterohepatic recirculation of piroxicam. Biopharmaceutics and Drug Disposition, 1996,17, 635-641.
29. Aabakken L, Olaussen B, Mowinckel P, Osnes M. Gastroduodenal lesions associated with two different piroxicam formulations: An endoscopic evaluation. Scandinavian J. of Gastroenterology, 1992, 27, 1049-1054.